Fedratinib is a type of medication called a kinase inhibitor. It works by blocking the activity of certain enzymes in the body, specifically Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). These enzymes are involved in the signaling pathways that control the growth and survival of blood cells.

In some blood cancers, such as myelofibrosis, JAK2 is abnormally active, leading to the uncontrolled growth of abnormal blood cells and scarring in the bone marrow. By inhibiting JAK2, fedratinib helps reduce the abnormal signaling, slows down the production of abnormal cells, and can help decrease symptoms like enlarged spleen and other related problems. This can improve quality of life and help manage the disease, although it may not cure it.

fedratinib

Common brand names

Approved use in